Liver disease, coagulation testing, and hemostasis

Area of Science:

• Hepatology
• Hematology
• Transfusion Medicine

Background:

• Coagulation testing abnormalities are common in patients with liver disease.
• Current practices often rely on outdated thresholds for blood product administration.

Purpose of the Study:

• To review the evidence on coagulation testing in liver disease.
• To evaluate the correlation between test results and actual hemostasis.
• To assess the efficacy of fresh frozen plasma (FFP) in preventing bleeding.

Main Methods:

• Literature review of studies on coagulation tests in liver disease.
• Analysis of evidence linking test abnormalities to bleeding risk.
• Examination of the rationale and effectiveness of FFP administration protocols.

Main Results:

• Coagulation test abnormalities in liver disease lack correlation with hemostasis and do not predict bleeding.
• The "1.5x" prothrombin time/international normalized ratio threshold for FFP/FP administration is historically inaccurate and ineffective.
• FFP/FP does not correct minimally prolonged clotting times or adequately prevent bleeding from procedures like liver biopsy.

Conclusions:

• Rethinking the interpretation and clinical utility of coagulation tests in liver disease is necessary.
• Current transfusion strategies for FFP/FP based on standard coagulation parameters are not supported by evidence.
• Alternative approaches to managing bleeding risk in liver disease patients should be explored.